MALIGNANT NEOPLASM OLIGOPROGRESSION

MALIGNANT NEOPLASM OLIGOPROGRESSION was reported 199 times

MALIGNANT NEOPLASM OLIGOPROGRESSION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager [EPC] 1 0.0017
1 Poly(ADP-Ribose) Polymerase Inhibitor [EPC] 7 0.0003
2 Estrogen Receptor Antagonist [EPC] 12 0.0003
3 CTLA-4-directed Blocking Antibody [EPC] 14 0.0003
4 Platinum-based Drug [EPC] 54 0.0002
5 Programmed Death Receptor-1 Blocking Antibody [EPC] 19 0.0002
6 Microtubule Inhibitor [EPC] 19 0.0001
7 Programmed Death Ligand-1 Blocker [EPC] 2 0.0001
8 Vascular Endothelial Growth Factor Inhibitor [EPC] 17 0.0001
9 Folate Analog Metabolic Inhibitor [EPC] 25 0.0001
10 HER2/neu Receptor Antagonist [EPC] 3 0.0000
11 Kinase Inhibitor [EPC] 22 0.0000
12 Topoisomerase Inhibitor [EPC] 3 0.0000
13 RANK Ligand Inhibitor [EPC] 6 0.0000
14 Aromatase Inhibitor [EPC] 3 0.0000
15 Angiotensin Converting Enzyme Inhibitor [EPC] 3 0.0000
16 Nucleoside Metabolic Inhibitor [EPC] 5 0.0000
17 Leukocyte Growth Factor [EPC] 2 0.0000
18 Androgen Receptor Inhibitor [EPC] 1 0.0000
19 Vitamin D [EPC] 4 0.0000
20 Vitamin B12 [EPC] 4 0.0000
21 Vitamin C [EPC] 5 0.0000
22 Nitrate Vasodilator [EPC] 1 0.0000
23 Dietary Cholesterol Absorption Inhibitor [EPC] 1 0.0000
24 Sodium-Glucose Cotransporter 2 Inhibitor [EPC] 1 0.0000
25 Alkylating Drug [EPC] 2 0.0000
26 Sulfonylurea [EPC] 1 0.0000
27 Dihydropyridine Calcium Channel Blocker [EPC] 2 0.0000
28 Xanthine Oxidase Inhibitor [EPC] 1 0.0000
29 HMG-CoA Reductase Inhibitor [EPC] 2 0.0000
30 Platelet Aggregation Inhibitor [EPC] 3 0.0000
31 Atypical Antipsychotic [EPC] 2 0.0000
32 Factor Xa Inhibitor [EPC] 1 0.0000
33 Osmotic Laxative [EPC] 1 0.0000
34 Angiotensin 2 Receptor Blocker [EPC] 1 0.0000
35 Nonsteroidal Anti-inflammatory Drug [EPC] 4 0.0000
36 Corticosteroid [EPC] 3 0.0000
37 Proton Pump Inhibitor [EPC] 1 0.0000
38 Benzodiazepine [EPC] 1 0.0000